BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17429046)

  • 1. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 2. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 4. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
    Banikazemi M; Desnick RJ
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
    [No Abstract]   [Full Text] [Related]  

  • 5. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
    Basic-Jukic N; Kes P; Mokos I; Coric M
    Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 7. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
    del Toro N; Milán JA; Palma A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
    [No Abstract]   [Full Text] [Related]  

  • 8. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1-7.
    Politei J
    Virchows Arch; 2006 Jun; 448(6):873. PubMed ID: 16523259
    [No Abstract]   [Full Text] [Related]  

  • 9. Agalsidase beta (Fabrazyme) for Fabry disease.
    Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
    [No Abstract]   [Full Text] [Related]  

  • 10. Anderson-Fabry disease: enzyme replacement therapy.
    Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
    Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosis and management of kidney involvement in Fabry disease.
    Warnock DG; West ML
    Adv Chronic Kidney Dis; 2006 Apr; 13(2):138-47. PubMed ID: 16580615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 13. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
    Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
    J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease: dose matters.
    Warnock DG; Mauer M
    J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 17. [Results of enzyme replacement therapy in Fabry disease nephropathy].
    Dussol B
    Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
    Germain DP
    Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
    [No Abstract]   [Full Text] [Related]  

  • 19. Fabry disease in an oligosymptomatic male.
    Altarescu G; Elstein D
    Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
    [No Abstract]   [Full Text] [Related]  

  • 20. Fabry disease: is there a role for enzyme replacement therapy?
    Mehta AB
    J Intern Med; 2013 Oct; 274(4):329-30. PubMed ID: 23662843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.